Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:05 pm Purchase |
2024-09-30 | 13G | Generation Asia I Acquisition Limited GAQ |
Blue Owl Capital Holdings LP | 573,000 7.310% |
573,000 (New Position) |
Filing History |
| 2024-11-14 5:05 pm Purchase |
2024-09-30 | 13G | African Agriculture Holdings Inc. AAGR |
Blue Owl Capital Holdings LP | 3,119,625 5.390% |
3,119,625 (New Position) |
Filing History |
| 2024-11-14 5:05 pm Purchase |
2024-09-30 | 13G | Context Therapeutics Inc. CNTX |
Blue Owl Capital Holdings LP | 5,411,290 7.220% |
5,411,290 (New Position) |
Filing History |
| 2024-11-14 5:05 pm Purchase |
2024-09-30 | 13G | AEON Biopharma, Inc. AEON |
Blue Owl Capital Holdings LP | 46,406 8.450% |
46,406 (New Position) |
Filing History |
| 2024-02-14 9:06 pm Purchase |
2023-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
Blue Owl Capital Holdings LP | 1,234,760 5.320% |
1,234,760 (New Position) |
Filing History |
| 2024-02-14 9:05 pm Purchase |
2023-12-31 | 13G | Orchard Therapeutics plc ORTX |
Blue Owl Capital Holdings LP | 15,596,600 6.850% |
15,596,600 (New Position) |
Filing History |
| 2024-02-14 9:02 pm Purchase |
2023-12-31 | 13G | Repare Therapeutics Inc. RPTX |
Blue Owl Capital Holdings LP | 3,122,499 7.410% |
3,122,499 (New Position) |
Filing History |
| 2024-02-14 9:01 pm Purchase |
2023-12-31 | 13G | Cullinan Oncology, Inc. CGEM |
Blue Owl Capital Holdings LP | 3,419,842 7.990% |
3,419,842 (New Position) |
Filing History |
| 2024-02-14 8:57 pm Purchase |
2023-12-31 | 13G | Larimar Therapeutics, Inc. LRMR |
Blue Owl Capital Holdings LP | 3,414,468 7.780% |
3,414,468 (New Position) |
Filing History |
| 2024-02-14 8:56 pm Purchase |
2023-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Blue Owl Capital Holdings LP | 1,493,252 5.740% |
1,493,252 (New Position) |
Filing History |
| 2024-02-14 8:55 pm Purchase |
2023-12-31 | 13G | Pliant Therapeutics, Inc. PLRX |
Blue Owl Capital Holdings LP | 3,004,199 5.020% |
3,004,199 (New Position) |
Filing History |
| 2024-02-14 8:51 pm Purchase |
2023-12-31 | 13G | Tourmaline Bio, Inc. TRML |
Blue Owl Capital Holdings LP | 1,332,302 6.550% |
1,332,302 (New Position) |
Filing History |